文献速递核素与放射性配体治疗放射性药物与辐射防护

基于90Y-DOTATOC剂量学的个体化肽受体放射性核素治疗

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.
PubMed 文献 · J Nucl Med · 2018-03-09

这项前瞻性2期试验在生长抑素受体阳性肿瘤患者中,采用90Y-DOTATOC PET/CT与轫致辐射SPECT/CT进行肾脏剂量学评估,并据此调整后续周期给药活度。结果显示每周期肾脏辐射剂量在患者间差异很大(0.32–3.0 mGy/MBq),20例成人中17例(85%)第二、三周期给药活度较起始活度调整至少20%。

要点

  • 90Y-DOTATOC治疗中每周期肾脏剂量在患者间差异大,范围为0.32–3.0 mGy/MBq。
  • 20例成人中17例(85%)在第二、三周期给药活度较起始调整至少20%。
  • 该剂量学方法无需氨基酸输注即可用于90Y-DOTATOC肾脏剂量评估。

核心结论

  • 使用90Y-DOTATOC飞行时间PET/CT与轫致辐射SPECT/CT进行肾脏剂量学评估是可行的,且对治疗周期的给药活度有显著影响。

研究设计与样本

  • 前瞻性2期试验,纳入生长抑素受体阳性肿瘤患者,90Y-DOTATOC每6–8周给药1次、共3个周期。
  • 第一周期成人给予4.4 GBq、儿童给予1.85 GBq/m2,后续周期依据前一周期剂量学调整,使肾脏总剂量不超过23 Gy、骨髓剂量不超过2 Gy。
  • 肾脏剂量由系列显像确定:治疗后5小时行飞行时间90Y-DOTATOC PET/CT,并在6、24、48、72小时行90Y-DOTATOC轫致辐射SPECT/CT。

主要发现

  • 每周期90Y-DOTATOC治疗的肾脏辐射剂量在患者间高度可变,范围为0.32–3.0 mGy/MBq。
  • 20例接受第二和第三治疗周期的成人患者中,17例(85%)的给药活度较起始给药活度调整至少20%。

关键数值与推荐

  • 第一周期给药活度:成人4.4 GBq,儿童1.85 GBq/m2;后续周期按前一周期剂量学调整。
  • 剂量限值:肾脏总剂量不超过23 Gy,骨髓剂量不超过2 Gy。
  • 肾脏剂量计算:将时间积分活度(来自90Y-DOTATOC肾脏清除拟合双指数曲线)乘以每次衰变释放能量,再除以肾脏质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pretherapy PET with 86Y-DOTATOC is considered the ideal dosimetry protocol for 90Y-DOTATOC therapy; however, its cost, limited availability, and need for infusion of amino acids to mimic the therapy administration limit its use in the clinical setting. The goal of this study was to develop a dosimetric method for 90Y-DOTATOC using 90Y-DOTATOC PET/CT and bremsstrahlung SPECT/CT and to determine whether dosimetry-based administered activities differ significantly from standard administered activities. Methods: This was a prospective phase 2 trial of 90Y-DOTATOC therapy in patients with somatostatin receptor-positive tumors. 90Y-DOTATOC was given in 3 cycles 6-8 wk apart. In the first cycle of therapy, adults received 4.4 GBq and children received 1.85 GBq/m2; the subsequent administered activities were adjusted according to the dosimetry of the preceding cycle so as not to exceed a total kidney dose of 23 Gy and bone marrow dose of 2 Gy. The radiation dose to the kidneys was determined from serial imaging sessions consisting of time-of-flight 90Y-DOTATOC PET/CT at 5 h after therapy and 90Y-DOTATOC bremsstrahlung SPECT/CT at 6, 24, 48, and 72 h. The PET/CT data were used to measure the absolute concentration of 90Y-DOTATOC and to calibrate the bremsstrahlung SPECT kidney clearance data. The radiation dose to the kidneys was determined by multiplying the time-integrated activity (from the fitted biexponential curve of renal clearance of 90Y-DOTATOC) with the energy emitted per decay, divided by the mass of the kidneys. Results: The radiation dose to the kidneys per cycle of 90Y-DOTATOC therapy was highly variable among patients, ranging from 0.32 to 3.0 mGy/MBq. In 17 (85%) of the 20 adult patients who received the second and the third treatment cycles of 90Y-DOTATOC, the administered activity was modified by at least 20% from the starting administered activity. Conclusion: Renal dosimetry of 90Y-DOTATOC is feasible using 90Y-DOTATOC time-of-flight PET/CT and bremsstrahlung SPECT/CT and has a significant impact on the administered activity in treatment cycles.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Menda Y, Madsen MT, O'Dorisio TM, et al. 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med. 2018. PMID: 29523629. doi:10.2967/jnumed.117.202903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。